ALLOVIR, INC.

antiviral cell therapy products in the nature of virus-specific T cells; antiviral cell therapy products for restoration and enhancement of patients' immune systems in the nature of T cells; antiviral cell therapy products for restoration and enhancement of patients' immune systems in the nature of virus-specific T cells; antiviral allogeneic cell therapy products in the nature of T cells; antiviral allogeneic cell therapy products in the nature of virus-specific T cells; antiviral cells for medical use; antiviral T cells for medical use; antiviral virus-specific T cells for medical use; antiviral immunotherapeutic agents for restoring viral immunity in immunocompromised patients; antiviral immunotherapeutic agents, namely T cells, for restoring viral immunity in immunocompromised patients; antiviral immunotherapeutic agents, namely allogenic T cells, for restoring viral immunity in immunocompromised patients; antiviral immunotherapeutic agents, namely virus-specific T cells, for restoring viral immunity in immunocompromised patients

Class 005: antiviral cell therapy products in the nature of virus-specific T cells; antiviral cell therapy products for restoration and enhancement of patients' immune systems in the nature of T cells; antiviral cell therapy products for restoration and enhancement of patients' immune systems in the nature of virus-specific T cells; antiviral allogeneic cell therapy products in the nature of T cells; antiviral allogeneic cell therapy products in the nature of virus-specific T cells; antiviral cells for medical use; antiviral T cells for medical use; antiviral virus-specific T cells for medical use; antiviral immunotherapeutic agents for restoring viral immunity in immunocompromised patients; antiviral immunotherapeutic agents, namely, T cells, for restoring viral immunity in immunocompromised patients; antiviral immunotherapeutic agents, namely, allogenic T cells, for restoring viral immunity in immunocompromised patients; antiviral immunotherapeutic agents, namely, virus-specific T cells, for restoring viral immunity in immunocompromised patients; Class 042: Research and development in the pharmaceutical and biotechnology fields

Research and development in the pharmaceutical and biotechnology fields

Medical analysis services relating to the administration of cell therapies, namely, T-cell therapies